From ESMO Breast Cancer 2023:
Patients given neoadjuvant atezolizumab alongside chemotherapy for stage II–III triple-negative breast cancer are more likely to achieve pathological complete response but do not have better survival
Welcome to OncologyPRO – educational and scientific content for ESMO Members. Participants of some ESMO Meetings will have access to the Meeting resources section—limited to the meeting you attended. To gain full access to all the resources on this website, you must be an ESMO Member.
Please sign in using the username and password you created. To ensure a seamless browsing experience, we suggest that you sign in at the start of your visit.
I have an ESMO account
Create a new account
Not yet an ESMO Member? Find out more about the benefits offered to ESMO Members.
If you have been an ESMO Member or have attended an ESMO event in the past, you already have an ESMO account and there is no need to create another.